

"The first and only urinary catheter, which, through additional functions, prevents infections, increases quality of life of patients and enhances nurses' work efficiency "







THE PROBLEM



Urinary catheters resolve the basic problem, but create new ones immediately. They are linked to extremely high infection risks, due to non-aseptic insertion, non-hygienic catheter management, open drainage system, biofilm creation, suppressed natural protective mechanism of the bladder and concentrated residual urine. Common catheter management procedures are highly protocolized, but too many times inadequate. Catheters lead to a sharp decline in the quality of life and lead to a high number of emergency visits.



219M Foley catheters / year (EU & USA)



15-25% hospitalized patients receive a urinary catheter



75% hospital acquired UTIs are associated with a urinary catheter



> **14.000** Deaths / year (EU)



1.5 bn€ annual direct costs (EU)

THE SOLUTION



T-control is a Foley catheter, which - thanks to a fully integrated valve - controls the urine flow in every moment.

- It permits to close urine flow and enables patients to use a common toiled instead of using a urine collection bag.
- It enhances the catheter insertion technique for nurses, making it easier, faster and with lower risk of losing asepticity during the procedure.

KEY BENEFITS





Multifactorial infection prevention



Improved quality of life



Increased patient freedom



Reduction of occupational risks



Increased process efficiency

MILESTONES

2014 Foundation

2016 EU Patent Approval

2018 USA Patent Approval

2018 Prototype readiness

2019 Product Manufacturing

2020 Clinical Validation

2020 **CE Mark**

2020 Pre-marketing & test-launch

2021 International development

FUNDS RAISED



- 60k€ FFF
- 50k€ Headstart EIT Health
- 50k€ SME Instrument Phase I

KEYMETRICS

783M USD Total market

181M€ Beachhead Market (Prostate hyperplasia, EU & USA)

70% Gross Margin

2022 Break-even

5M USD Pre-money value

FUNDING GOALS



- 71% Clinical Studies
- 21% Product Manufacturing
- 8% Registration

MANAGING TEAM



Szilvia Endrényi CEO



Manuel Luque CTO in

















